
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.






